Daptomycin

被引：134

作者：

Raja, A ^{[1
]}

LaBonte, J ^{[1
]}

Lebbos, J ^{[1
]}

Kirkpatrick, P ^{[1
]}

机构：

[1] Decis Resources Inc, Waltham, MA 02453 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2003年 / 2卷 / 12期

关键词：

D O I：

10.1038/nrd1258

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

In September 2003, daptomycin (Cubicin; Cubist Pharmaceuticals) — the first member of a new class of antibiotics — was approved by the US FDA for the treatment of infections caused by Gram-positive bacteria. Will its ability to treat infections resistant to many current antibiotics lead to significant market success?

引用

页码：943 / 944

页数：2

共 7 条

[1] The future challenges facing the development of new antimicrobial drugs [J].